<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414167</url>
  </required_header>
  <id_info>
    <org_study_id>K23DK071646</org_study_id>
    <nct_id>NCT00414167</nct_id>
  </id_info>
  <brief_title>Craving, Binge Eating and Obesity</brief_title>
  <official_title>Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <brief_summary>
    <textblock>
      This research study is designed to look at the effectiveness of bupropion for reducing binge
      eating in overweight persons with binge eating problems. Participants in the study will
      receive either bupropion or placebo (&quot;sugar&quot; pill, inactive medication) as an outpatient for
      eight weeks. In addition, participants will be given the option to receive 8 weeks of free
      behavioral weight loss treatment. This treatment, known to be effective for reducing binge
      eating and helping people lose weight, will be administered following the medication phase
      and at no cost.

      It is expected that compared to placebo, bupropion will produce greater reductions in binge
      eating.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is an 8-week randomized placebo-controlled trial to test the efficacy of
      bupropion in treating overweight women with binge eating disorder (BED). Bupropion is an
      antidepressant that has demonstrated efficacy in smoking cessation and some efficacy in
      obesity treatment. Since cravings and depressed mood are hypothesized to contribute to binge
      eating episodes, bupropion is a promising psychopharmacological agent in treating binge
      eating and reducing weight. It is hypothesized that compared to placebo, bupropion will
      produce significantly greater reductions in the frequency of binge eating. Secondary goals
      are to explore interrelationships between treatment and changes in cravings, frequency of
      binge episodes, emotional eating, and weight loss. Following the medication phase of the
      trial, all patients will be offered 8 weeks of behavioral weight loss treatment administered
      by doctoral-level psychologists specializing in eating disorders and weight management.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Binge Eating Episodes</measure>
    <time_frame>One week (at post treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent BMI Loss</measure>
    <time_frame>8 weeks (baseline and 8 weeks)</time_frame>
    <description>Percent loss in Body Mass Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Binge Eating Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion</intervention_name>
    <description>300 mg per day for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>wellbutrin</other_name>
    <other_name>zyban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 25-50

          -  Able to travel to clinical site (New Haven, CT) for bi-weekly visits.

        Exclusion Criteria:

          -  Predisposition to seizures

          -  History of anorexia or bulimia nervosa

          -  Current Type I or Type II diabetes mellitus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marney A. White, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2006</study_first_submitted>
  <study_first_submitted_qc>December 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2006</study_first_posted>
  <results_first_submitted>October 22, 2012</results_first_submitted>
  <results_first_submitted_qc>February 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2014</results_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Marney A. White</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Binge eating</keyword>
  <keyword>Obesity</keyword>
  <keyword>Medication</keyword>
  <keyword>Craving</keyword>
  <keyword>Emotional eating</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
    <mesh_term>Bulimia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixty-one overweight and obese women with BED were recruited from the community via advertisements. Participants were enrolled from November 2006 to December 2010. Assessments and clinic appointments were held in a medical school research clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bupropion (300 mg/d)</title>
          <description>Bupropion
bupropion : 300 mg per day for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo : Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupropion</title>
          <description>Bupropion
bupropion : 300 mg per day for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Placebo : Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.2" spread="12.1"/>
                    <measurement group_id="B2" value="43.1" spread="13.0"/>
                    <measurement group_id="B3" value="44.2" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Binge Eating Episodes</title>
        <time_frame>One week (at post treatment)</time_frame>
        <population>Baseline forward imputation for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Binge Eating Episodes</title>
          <population>Baseline forward imputation for missing data.</population>
          <units>episodes/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.2"/>
                    <measurement group_id="O2" value="1.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent BMI Loss</title>
        <description>Percent loss in Body Mass Index</description>
        <time_frame>8 weeks (baseline and 8 weeks)</time_frame>
        <population>Baseline values imputed forward for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupropion</title>
            <description>Bupropion
bupropion : 300 mg per day for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo : Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent BMI Loss</title>
          <description>Percent loss in Body Mass Index</description>
          <population>Baseline values imputed forward for missing data.</population>
          <units>Percent loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.6"/>
                    <measurement group_id="O2" value="0.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupropion</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marney A. White</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>203-785-4349</phone>
      <email>marney.white@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

